To overcome the limitations of the clinical use of neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), scientists have been trying to create their low-molecular-weight mimetics having improved pharmacokinetic properties and lacking side effects of full-sized proteins since the 90s of the last century. The efforts of various research groups have led
The search for new highly-effective, fast-acting antidepressant drugs is extremely relevant. Brain
derived neurotrophic factor (BDNF) and signaling through its tropomyosin-related tyrosine kinase B (TrkB)
receptor, represents one of the most promising therapeutic targets for treating depression. BDNF is a key regulator
of neuroplasticity in the hippocampus and the prefrontal cortex, the dysfunction of which is considered to be
the main pathophysiological hallmark of this disorder. BDNF itself has no favorable drug-like properties due to
poor pharmacokinetics and possible adverse effects. The design of small, proteolytically stable BDNF mimetics
might provide a useful approach for the development of therapeutic agents. Two small molecule BDNF mimetics
with antidepressant-like activity have been reported, 7,8-dihydroxyflavone and the dimeric dipeptide mimetic of
BDNF loop 4, GSB-106. The article reflects on the current literature on the role of BDNF as a promising therapeutic
target in the treatment of depression and on the current advances in the development of small molecules on
the base of this neurotrophin as potential antidepressants.
On the basis of the structure of beta-turn of loop 2 of brain-derived neurotrophic factor (BDNF), its new dimeric dipeptide mimetic bis-(N-hexanoyl-L-seryl-L-lysine) hexamethylenediamide (GTS-201) was created. It activated TrkB and Erk, did not activate Akt, and exhibited neuroprotective activity in vitro at concentrations of 10-10 M. Unlike the mimetics that activate Erk and Akt, GTS-201 did not exhibit antidepressant properties. For the manifestation of the antidepressant activity of BDNF mimetics, the activation of its both major signaling pathways is required.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.